Presentation of HER2/neu Vaccine Development Program at Third Annual Cancer Vaccines and Active Immunity Summit, Boston, June 27-29, 2012
June 26, 2012 09:20 ET
|
TapImmune Inc.
SEATTLE, June 26, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc (OTCBB:TPIV) has announced it will present a poster at the Third Annual Cancer Vaccines and Active Immunotherapy Summit in Boston describing...
TapImmune Inc. to Present at NYC Medtech Forum on June 14, 2012
June 13, 2012 12:43 ET
|
TapImmune Inc.
SEATTLE, June 13, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (TPIV.OB), a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and...
TapImmune Announces the Appointment of James W. Fuller to the Board of Directors
May 18, 2012 09:15 ET
|
TapImmune Inc.
SEATTLE, May 18, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has pleasure in announcing the appointment of James W. Fuller to the Board of Directors.
James (Jim) Fuller has over 30 years of...
Phase I Clinical Trials on HER2/neu Antigens to Start at Mayo Clinic
May 04, 2012 09:10 ET
|
TapImmune Inc.
SEATTLE, May 4, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has announced that following recent IRB approval a Phase I Clinical Trial on a novel set of HER2/neu Class II antigens will start...
TapImmune Announces the Appointment of Mark Reddish to the Board of Directors
April 30, 2012 09:30 ET
|
TapImmune Inc.
SEATTLE, April 30, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has pleasure in announcing the appointment of Mark Reddish to the Board of Directors. Mark is currently Vice President of...
TapImmune Announces the Appointment of Mr. George Cardona as Strategic Advisor to the Board
April 19, 2012 09:30 ET
|
TapImmune Inc.
SEATTLE, April 19, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has pleasure in announcing the appointment of George Cardona as a Strategic Advisor to the Board on corporate strategy and...
TapImmune Licenses HER2/neu Antigen Technology from Mayo Clinic for Incorporation Into a Vaccine to Treat HER2/neu Breast Cancer
April 16, 2012 06:00 ET
|
TapImmune Inc.
SEATTLE, Wash., April 16, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has announced that it has signed an Exclusive Agreement with the Mayo Foundation for Education & Research, Rochester,...
TapImmune Appoints Dr. Robert Florkiewicz as Senior Director of Molecular Biology & Virology
April 11, 2012 09:20 ET
|
TapImmune Inc.
SEATTLE, April 11, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has announced that Robert Florkiewicz, Ph.D., has been appointed Senior Director of Molecular Biology & Virology.
"Bob has...
TapImmune Inc. to Present at BioPartnering North America
February 27, 2012 09:30 ET
|
TapImmune Inc.
SEATTLE, Feb. 27, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a vaccine technologies company specializing in the development of innovative immunotherapeutics and vaccines in the areas of...
TapImmune Chairman and CEO Provides Corporate Update to Current and Future Shareholders
January 30, 2012 09:30 ET
|
TapImmune Inc.
SEATTLE, Jan. 30, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), Chairman and CEO is pleased to provide this corporate update to our shareholders and other interested parties.
I am pleased to...